JP2024535745A - Ａｍｐｋ活性化剤として有用なチアジアゾロン誘導体 - Google Patents

Ａｍｐｋ活性化剤として有用なチアジアゾロン誘導体 Download PDF

Info

Publication number
JP2024535745A
JP2024535745A JP2024514006A JP2024514006A JP2024535745A JP 2024535745 A JP2024535745 A JP 2024535745A JP 2024514006 A JP2024514006 A JP 2024514006A JP 2024514006 A JP2024514006 A JP 2024514006A JP 2024535745 A JP2024535745 A JP 2024535745A
Authority
JP
Japan
Prior art keywords
compound
methyl
oxo
chlorophenyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024514006A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024535745A5 (enExample
Inventor
エドランド，トーマス
ウェストマン，ヤコブ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Betagenon AB
Original Assignee
Betagenon AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betagenon AB filed Critical Betagenon AB
Publication of JP2024535745A publication Critical patent/JP2024535745A/ja
Publication of JP2024535745A5 publication Critical patent/JP2024535745A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Peptides Or Proteins (AREA)
JP2024514006A 2021-09-02 2022-09-01 Ａｍｐｋ活性化剤として有用なチアジアゾロン誘導体 Pending JP2024535745A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2112529.9A GB202112529D0 (en) 2021-09-02 2021-09-02 New compounds
GB2112529.9 2021-09-02
PCT/GB2022/052234 WO2023031609A1 (en) 2021-09-02 2022-09-01 Thiadiazolone derivatives useful as ampk activator

Publications (2)

Publication Number Publication Date
JP2024535745A true JP2024535745A (ja) 2024-10-02
JP2024535745A5 JP2024535745A5 (enExample) 2025-09-05

Family

ID=78076730

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024514006A Pending JP2024535745A (ja) 2021-09-02 2022-09-01 Ａｍｐｋ活性化剤として有用なチアジアゾロン誘導体

Country Status (11)

Country Link
US (1) US20250136563A1 (enExample)
EP (1) EP4396171A1 (enExample)
JP (1) JP2024535745A (enExample)
KR (1) KR20240055039A (enExample)
CN (1) CN118510762A (enExample)
AU (1) AU2022336441A1 (enExample)
CA (1) CA3230307A1 (enExample)
GB (1) GB202112529D0 (enExample)
IL (1) IL310871A (enExample)
MX (1) MX2024002674A (enExample)
WO (1) WO2023031609A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3075388T3 (en) 2019-10-18 2026-08-04 Betagenon Ab New formulations
GB202015585D0 (en) 2020-10-01 2020-11-18 Betagenon Bio Ab New compounds
WO2025252672A1 (en) * 2024-06-03 2025-12-11 Betagenon Ab Use of tryptophan and metabolites thereof as biomarkers for treatment methods

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008538772A (ja) * 2005-04-25 2008-11-06 ハー・ルンドベック・アクチエゼルスカベット Ｎ−チアゾール−２−イル−ベンズアミド誘導体のプロドラッグ
JP2009501775A (ja) * 2005-07-21 2009-01-22 ベタゲノン・エイビー 癌治療におけるチアゾール誘導体およびアナログの使用
WO2012033149A1 (ja) * 2010-09-10 2012-03-15 塩野義製薬株式会社 Ａｍｐｋ活性化作用を有するヘテロ環縮合イミダゾール誘導体
JP2012532854A (ja) * 2009-07-08 2012-12-20 バルティック バイオ アーベー 医薬として有用な化合物
WO2013108026A1 (en) * 2012-01-17 2013-07-25 Baltic Bio Ab Thiadiazolone derivatives useful in the treatment of diabetes
JP2013230986A (ja) * 2010-08-25 2013-11-14 Kyorin Pharmaceutical Co Ltd 新規ヒダントイン誘導体及びそれらを有効成分とする医薬
WO2020215156A1 (en) * 2019-04-26 2020-10-29 Risen (Suzhou) Pharma Tech Co., Ltd. Prodrugs of a cdk inhibitor for treating cancers
JP2023543924A (ja) * 2020-10-01 2023-10-18 ベタゲノン ビオ アーベー チアジアゾロン誘導体と、それらの糖尿病および関連疾患の治療のためのａｍｐｋアゴニストとしての使用

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008538772A (ja) * 2005-04-25 2008-11-06 ハー・ルンドベック・アクチエゼルスカベット Ｎ−チアゾール−２−イル−ベンズアミド誘導体のプロドラッグ
JP2009501775A (ja) * 2005-07-21 2009-01-22 ベタゲノン・エイビー 癌治療におけるチアゾール誘導体およびアナログの使用
JP2012532854A (ja) * 2009-07-08 2012-12-20 バルティック バイオ アーベー 医薬として有用な化合物
JP2013230986A (ja) * 2010-08-25 2013-11-14 Kyorin Pharmaceutical Co Ltd 新規ヒダントイン誘導体及びそれらを有効成分とする医薬
WO2012033149A1 (ja) * 2010-09-10 2012-03-15 塩野義製薬株式会社 Ａｍｐｋ活性化作用を有するヘテロ環縮合イミダゾール誘導体
WO2013108026A1 (en) * 2012-01-17 2013-07-25 Baltic Bio Ab Thiadiazolone derivatives useful in the treatment of diabetes
WO2020215156A1 (en) * 2019-04-26 2020-10-29 Risen (Suzhou) Pharma Tech Co., Ltd. Prodrugs of a cdk inhibitor for treating cancers
JP2023543924A (ja) * 2020-10-01 2023-10-18 ベタゲノン ビオ アーベー チアジアゾロン誘導体と、それらの糖尿病および関連疾患の治療のためのａｍｐｋアゴニストとしての使用

Also Published As

Publication number Publication date
US20250136563A1 (en) 2025-05-01
IL310871A (en) 2024-04-01
EP4396171A1 (en) 2024-07-10
CA3230307A1 (en) 2023-03-09
AU2022336441A1 (en) 2024-03-07
WO2023031609A1 (en) 2023-03-09
CN118510762A (zh) 2024-08-16
MX2024002674A (es) 2024-03-19
KR20240055039A (ko) 2024-04-26
GB202112529D0 (en) 2021-10-20

Similar Documents

Publication Publication Date Title
US20250136563A1 (en) Thiadiazolone derivatives useful as ampk activator
US12391661B2 (en) Cystine diamide analogs for the prevention of cystine stone formation in cystinuria
EP4222147B1 (en) Thiadiazolone derivatives and their use as ampk agonists for the treatment of diabetes and related disorders
JP2013527124A (ja) オピオイドの新規カルバマートアミノ酸およびペプチドプロドラッグならびにその使用
AU2016253911B2 (en) Carboxylic acid URAT1 inhibitor containing diarylmethane structure, preparation method and use thereof
US20220388955A1 (en) Ep2 antagonist
EP4244221B1 (en) Prodrug of pyrrolidone derivatives as glucokinase activator
US20170095525A1 (en) Conjugates and prodrugs for treating of cancer and inflammatory diseases
US20230141981A1 (en) Novel compounds and composition for targeted therapy of kidney-associated cancers
JP2009190971A (ja) ２−シアノピロリジン誘導体
US12453722B2 (en) Maleate of nicotinyl alcohol ether derivative, crystal form thereof, and application thereof
RU2481341C2 (ru) Кристаллические модификации 3-(1н-индол-3-ил)-4-[2-(4-метилпиперазин-1-ил)хиназолин-4-ил]пиррол-2,5-диона
EP1084120B1 (en) Cinnamoyl distamycin analogous derivatives, process for their preparation, and their use as antitumor agents
EP3438118B1 (en) Peptide derivative and use thereof
HK40092998B (en) Thiadiazolone derivatives and their use as ampk agonists for the treatment of diabetes and related disorders
HK40092998A (en) Thiadiazolone derivatives and their use as ampk agonists for the treatment of diabetes and related disorders
JP2025146849A (ja) エラフィブラノールの多形体
WO2024120448A1 (zh) 一种hdac抑制剂及其用途
CN112513003A (zh) 伊拉非诺盐
JP2003206297A (ja) メバロン酸誘導体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250828

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250828

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260515

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260519